Gina Mauro

Regardless of primary tumor site or disease stage, avelumab maintenance was able to elicit overall survival benefit versus best supportive care for platinum-treated urothelial cancer.

Data from the KEYNOTE-564 trial presented at ASCO indicate benefit of pembrolizumab therapy in patients with clear cell renal cell carcinoma who were receiving therapy in the adjuvant setting.

In a phase 1 study of the innate cell engager AFM13, all 4 patients with CD30-positive, relapsed/refractory Hodgkin lymphoma treated with the therapy achieved at least a partial response.

The selective MCL-1 inhibitor AMG 176 plus gilteritinib as a combination treatment synergistically targeted preclinical models of FLT3 internal tandem duplication–mutated acute myeloid leukemia.

Nivolumab in combination with paclitaxel showed clinical activity and a manageable safety profile when used as second-line therapy for patients with Epstein-Barr virus–related, microsatellite instability–high/mismatch repair deficient or PD-L1–positive advanced gastric cancer.

The early results showed that voruciclib led to a rapid decrease in the phosphorylation of proteins that promote MYC transcription and quickly decreases phosphorylation of MYC protein on Serine 62 (Ser62), which is a site implicated in stabilizing MYC in KRAS-mutant cancers.

Patients with metastatic renal cell carcinoma and brain metastases showed significant intracranial and extracranial responses with cabozantinib use.

Avelumab plus best supportive care as frontline maintenance therapy produced a favorable benefit-risk balance for Japanese patients with advanced urothelial cancer who did not progress on first-line chemotherapy.

Patients with KRAS G12C–mutated advanced non–small cell lung cancer show antitumor response and survival benefit with the KRAS G12C inhibitor sotorasib, formerly AMG 510.

A real-world study enlightens to the importance of NRG1 fusions in non–small cell lung cancer and provides possible steps forward.

Overall survival benefits were noted when ivosidenib tablets were used in previously treated patients with IDH1-mutant cholangiocarcinoma when compared against placebo, according to a phase 3 trial.

The allogeneic off-the-shelf CD22-directed T-cell product, UCART22, showed early signs of activity and no evidence of unexpected toxicities for adult patients with relapsed/refractory CD22-positive B-cell acute lymphoblastic leukemia.

The GP2/GM-CSF combination demonstrated a 100% disease-free survival at 5 years for patients with HER2/neu 3–positive disease who received adjuvant trastuzumab.

For women with heavily pretreated, postmenopausal advanced or metastatic estrogen receptor (ER)–positive breast cancer, amcenestrant prompted antitumor activity.

Impressive signals of efficacy, durable responses, overall survival rates, and a tolerable safety profile were all found for fam-trastuzumab deruxtecan-nxki to treat patients with HER2-positive metastatic breast cancer.

Treatment with oral paclitaxel, compared with the intravenous formulation, in combination with encequidar led to an estimated 26.5% reduction in the risk of death in patients with metastatic breast cancer, according to updated phase 3 findings of the KX-ORAX-001 trial.

Treatment with abemaciclib and standard endocrine therapy reduced the risk of invasive disease recurrence or death in patients with high-risk, early hormone receptor–positive, HER2-negative breast cancer.

The CAR T-cell therapy elicited a 92% ORR, with high rates of durable responses in patients with indolent non-Hodgkin lymphoma.

A novel CD20xCD3 bispecific antibody, odronextamab, continues to show intriguing antitumor activity and an acceptable safety profile in patients with relapsed/refractory B-cell non-Hodgkin lymphoma, including those who have previously received chimeric antigen receptor T-cell therapy.

Regardless of age, Selinexor induced a clinical benefit in patients with relapsed/refractory diffuse large B-cell lymphoma.

Treatment with trilaciclib prior to chemotherapy was found to significantly reduce the need for supportive care interventions in the management of severe neutropenia and grade 3/4 anemia induced by chemotherapy in patients with extensive-stage small cell lung cancer, compared with placebo.

Results from the phase 1/2 ALEXANDER study found the investigational CAR T-cell product AUTO3 in combination with pembrolizumab to have a tolerable safety profile and elicit durable complete responses in patients with relapsed/refractory diffuse large B-cell lymphoma.

Balstilimab as a single agent and combined with zalifrelimab demonstrated promising objective response rates, regardless of PD-L1 expression, and a tolerable safety profile in patients with recurrent or metastatic cervical cancer.

“Results from this study suggest that tisotumab vedotin has the potential to be a new therapy for patients with previously treated recurrent and/or metastatic cervical cancer,” said lead study author Robert L. Coleman, MD, FACOG, FACS.

In patients with metastatic castration-resistant prostate cancer (mCRPC) with PTEN loss, ipatasertib combined with abiraterone acetate (Zytiga) plus prednisone led to a significantly superior radiographic progression-free survival and antitumor activity.

First-line treatment with the third-generation ALK TKI was also associated with higher overall and intracranial response rates in patients with ALK-positive non–small cell lung cancer.

“With expanding options for patients with advanced RCC, the overall efficacy, safety, and quality of life benefits, as well as individual patient characteristics, are very important considerations when you select appropriate therapy.”

Cemiplimab demonstrated an objective response rate of 31% in patients with locally advanced basal cell carcinoma who progress on or are intolerant to hedgehog inhibitors.

Treatment with lenalidomide and rituximab improved progression-free survival, compared with placebo in patients ≥70 years old with indolent non-Hodgkin lymphoma.

Acalabrutinib alone and in combination with obinutuzumab significantly improved progression-free survival, compared with obinutuzumab plus chlorambucil in treatment-naïve patients with chronic lymphocytic leukemia